Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05001347 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
A Phase 2 study, sponsored by I-Mab Biopharma US Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT05001347 is a Phase 2 study that has completed, run by I-Mab Biopharma US Limited. The registered enrollment target is 25 participants.
The verdict
NCT05001347, a Phase 2 study, has completed, sponsored by I-Mab Biopharma US Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.
Interventions
- DRUG TJ004309
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2023-02-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05001347
The ClinicalTrials.gov registry entry for NCT05001347 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is I-Mab Biopharma US Limited, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TJ004309 is the first listed.
NCT05001347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05001347 about?
NCT05001347 is a clinical study titled "A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors". This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.
What is the current status of trial NCT05001347?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-11-02. Estimated completion is 2023-02-08.
What interventions are being tested in trial NCT05001347?
The interventions under investigation include: TJ004309 (DRUG).
Who is sponsoring clinical trial NCT05001347?
This trial is sponsored by I-Mab Biopharma US Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.